首頁
Accord Healthcare

8月 2026Accord Healthcare的市場佔有率分析

健康 > 生物技術和製藥

域名accord-healthcare.com

成立年份2008

僱員1001 - 5000

年度營收$500M - $1B

Accord Healthcare

Accord Healthcare（包含公司地區）

accord-healthcare.com

查看更多網站流量與參與度資訊

Accord Healthcare截至 8月 2026 的總收入為 500M - 1B

Accord Healthcare 熱門網域產生的總收入

Accord Healthcare 熱門網域 3 年內的總收入

Accord Healthcare 熱門網域的總收入

accord-healthcare.com500M - 1B

透過銷售情報查看更多內容

Accord Healthcare的熱門網域總造訪量

了解Accord Healthcare市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

子公司細目

accord-healthcare.com32.3K

透過銷售情報查看更多內容

Accord Healthcare的熱門網域平均造訪時長

分析Accord Healthcare參與度指標。

過去 3 個月平均造訪時長

子公司細目

accord-healthcare.com00:00:57

透過銷售情報查看更多內容

Accord Healthcare的熱門網域平均頁面瀏覽量

了解Accord Healthcare如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

子公司細目

accord-healthcare.com2.07

透過銷售情報查看更多內容

Accord Healthcare按網域劃分的熱門競爭對手

8月 2026的熱門類似網站，依相似度排名

amneal.com公司名Amneal僱員5001 - 10000總部美國, 新澤西州, Bridgewater年度營收> $1B訪問總量41.3K健康 > 生物技術和製藥

使用的熱門技術Accord Healthcare

这些是Accord Healthcare顶级域名使用的行业网站技术

付費廣告 (6)

PubMatic

內容管理系統 (4)

WordPress

小工具 (4)

reCAPTCHA

轉換與分析 (3)

Google Analytics

更多技術

10

檢視所有

新聞與訊號來自Accord Healthcare

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞Hipra partnered with Accord Healthcare on Sep 8th '26.Spanish company HIPRA Human Health (HIPRA) and UK-based Accord Healthcare have announced that Bimverax LP.8.1, a protein-based COVID-19 vaccine, will be available in the UK as part of the 2026/27 autumn vaccination program through a strategic partnership between the two companies.

新聞Novartis AG identified as competitor of Accord Healthcare on Aug 13th '26.LONDON, Aug 13 (Reuters) - Swiss drugmaker Novartis on Thursday defeated a bid to invalidate its patent for blockbuster heart drug Entresto, with London's High Court rejecting a claim by Intas Pharmaceuticals' Accord Healthcare which was planning a generic rival.

新聞Johnson & Johnson files suit against Accord Healthcare, Ltd..The challenged patents were previously asserted by Janssen against Accord and Bio-Thera in pending litigation in the District of Delaware, No. 1:26-cv-00222 (D. Del.) (previously reported Janssen Files First BPCIA Suit Over Simponi(R)(golimumab) Biosimilar).